Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 2/2024

Open Access 09-01-2024 | Chronic Lymphocytic Leukemia

Treatment of Richter’s Transformation with Novel Therapies

Authors: Amneet Bajwa, Alma Habib, Adam S. Kittai

Published in: Current Hematologic Malignancy Reports | Issue 2/2024

Login to get access

Abstract

Purpose of Review

This review presents recently published clinical trial data and ongoing investigations regarding the treatment of Richter’s transformation (RT).

Recent Findings

Recently, numerous approaches have been investigated for the treatment of RT including: traditional chemoimmunotherapy regimens combined with targeted agents such as BTKi and BCL2i; immunotherapy combined with targeted agents; non-covalent BTKis; bispecific T cell engagers; and CART therapy. In addition, various novel targeted agents are currently being studied for the treatment of RT in phase 1 and 2 clinical trials.

Summary

Standard of care treatment with chemoimmunotherapy for RT has limited efficacy in achieving durable remissions. Here, we review recent data on the use of combination treatments and targeted agents in RT. Although some progress has been made in the investigation to optimize treatment of RT, further study is needed to evaluate long term outcomes of recently published trials and test efficacy of upcoming novel agents.
Literature
1.
Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24(15):2343–51.PubMedCrossRef
2.
Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105(3):765–73.PubMedPubMedCentralCrossRef
3.
Pistoia V, Roncella S, Di Celle PF, Sessarego M, Cutrona G, Cerruti G, et al. Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. Blood. 1991;78(3):797–804.PubMedCrossRef
4.
Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, et al. Mantle cell lymphoma-variant Richter syndrome: detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years. Int J Cancer. 2016;139(10):2252–60.PubMedCrossRef
5.
Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774–82.PubMedPubMedCentralCrossRef
6.
Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391–401.PubMedCrossRef
7.
Ansell SM, Li CY, Lloyd RV, Phyliky RL. Epstein-Barr virus infection in Richter's transformation. Am J Hematol. 1999;60(2):99–104.PubMedCrossRef
8.
Favini C, Talotta D, Almasri M, Andorno A, Rasi S, Adhinaveni R, et al. Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. Br J Haematol. 2022;198(6):1016–22.PubMedPubMedCentralCrossRef
9.
• Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023;29(1):158–69. In this paper, Dr. Parry et al describe how RT transforms from CLL, deepening our understanding of the transformationm process.PubMedPubMedCentralCrossRef
10.
Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122(15):2673–82.PubMedCrossRef
11.
Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202–15.PubMedCrossRef
12.
Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783–90.PubMedPubMedCentralCrossRef
13.
• Kittai AS, Huang Y, Beckwith KA, Bhat SA, Bond DA, Byrd JC, et al. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib. Am J Hematol. 2023;98(1):56–65. This is one of the only studies that evaluated RT that had developed on small molecule inhibitors. Highlighting important clinical indications to consider RT development, and poor overall survival even in the era of modern therapy.PubMedCrossRef
14.
Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017;1(19):1584–8.PubMedPubMedCentralCrossRef
15.
Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239–43.PubMedCrossRef
16.
NCCN Clinical Practice Guidelines: histologic transformation (Richter’s) and progression. Version 2.2023. Accessed August 18 Tvmracvotg, visit NCCN.org.
17.
Smyth E, Eyre TA, Cheah CY. Emerging therapies for the management of Richter transformation. J Clin Oncol. 2023;41(2):395–409.PubMedCrossRef
18.
Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018;180(2):259–66.PubMedCrossRef
19.
Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, v Tresckow J, et al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2021;35(1):169–76.PubMedCrossRef
20.
Elnair R, Ellithi M, Kallam A, Shostrom V, Bociek RG. Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database. Ann Hematol. 2021;100(10):2513–9.PubMedCrossRef
21.
Abrisqueta P, Delgado J, Alcoceba M, Oliveira AC, Loscertales J, Hernández-Rivas JA, et al. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol. 2020;190(6):854–63.PubMedCrossRef
22.
Popp HD, Flach J, Brendel S, Ruppenthal S, Kleiner H, Seifarth W, et al. Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. Leuk Lymphoma. 2019;60(3):795–804.PubMedCrossRef
23.
Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, et al. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2021;106(11):2845–52.PubMedCrossRef
24.
Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125(10):1676–8.PubMedPubMedCentralCrossRef
25.
Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, et al. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study. Lancet Haematol. 2021;8(12):e912–e21.PubMedCrossRef
26.
Al-Sawaf O, Robrecht S, Stumpf J, Fink A-M, Ritgen M, Johansson P, et al. The CLL-RT1 trial: a multicenter phase-2 trial of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for patients with Richter transformation. Hematol Oncol. 2021;39(S2).
27.
Appleby N, Eyre TA, Cabes M, Jackson A, Boucher R, Yates F, et al. The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer. 2019;19(1):471.PubMedPubMedCentralCrossRef
28.
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–200.PubMedCrossRef
29.
Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049–60.PubMedPubMedCentralCrossRef
30.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–80.PubMedCrossRef
31.
Seymour JF, Kipps TJ, Eichhorst BF, D’Rozario J, Owen CJ, Assouline S, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140(8):839–50.PubMedPubMedCentralCrossRef
32.
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139(22):3278–89.PubMedCrossRef
33.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.PubMedPubMedCentralCrossRef
34.
Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022;139(5):686–9.PubMedPubMedCentralCrossRef
35.
•• Davids MS, Rogers KA, Jain N, Tyekucheva S, Ren Y, Carey C, et al. Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome. Hematol Oncol. 2023;41(S2):466–8. This trial showed impressive response rates combining venetoclax plus REPOCH, but due to safety concerns has been amended to only treat patients with venetoclax plus RCHOP. Updated results are pending.CrossRef
36.
Allan JN, Bhavsar EB, Vaisitti T, Sarno V, Liu Y, Arruga F, et al. CD79b Expression in Richter's Transformation. Blood. 2019;134(Supplement_1):4279.CrossRef
37.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901.PubMedCrossRef
38.
Lewis KL, Cheah CY. Non-covalent BTK inhibitors-the new BTKids on the block for B-cell malignancies. J Pers Med. 2021;11(8).
39.
Wierda WG, Lewis DJ, Ghia P, Shah NN, Coombs CC, Cheah CY, et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1/2 BRUIN study. Blood. 2022;140(Supplement 1):846–9.CrossRef
40.
Woyach J, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood. 2019;134:4298.CrossRef
41.
Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematol. 2019;6(2):e67–78.PubMedCrossRef
42.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, et al. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023;7(10):1958–66.PubMedCrossRef
43.
Tam C, Munoz J, Cull G, Opat S, Allewelt H, Zhang X, et al. Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia. Hemasphere. 2023;7(4):e870.PubMedPubMedCentralCrossRef
44.
•• Montillo M, Rossi D, Zinzani PL, Motta M, Gaidano G, Quaresmini G, et al. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome. J Clin Oncol. 2023;41(16_suppl):7502. This trial was recently presented at the ASCO national conference, with impressive response rates observed using immunotherapy in atezolizumab plus venetoclax.CrossRef
45.
Heyman BM, Choi MY, Kipps TJ. Obinutuzumab, high-dose methylprednisolone (HDMP), and lenalidomide for the treatment of patients with Richter's syndrome. Cancers (Basel). 2022;14(24).
46.
Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, et al. Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. Br J Haematol. 2020;188(4):e33–e6.PubMedCrossRef
47.
Itchaki G, Brown JR. Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26(5):633–50.PubMedCrossRef
48.
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.PubMedPubMedCentralCrossRef
49.
Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–55.PubMedPubMedCentralCrossRef
50.
Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, et al. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021;137(24):3378–89.PubMedCrossRef
51.
Ryan CE, Crombie JL, Tyekucheva S, McDonough MM, Montegaard JS, Kim AI, et al. Updated results from a phase I/II study of duvelisib and venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or Richter's syndrome (RS). Blood. 2022;140(Supplement 1):9871–2.CrossRef
52.
Shouse G, Siddiqi T, Popplewell LL, Muir A, Melgar I, Orand K, et al. A phase I trial of PI3Kαδ inhibitor copanlisib in combination with nivolumab in patients with Richter's transformation (RT) or transformed non-Hodgkin lymphoma (tNHL). Blood. 2022;140(Supplement 1):6633–4.CrossRef
53.
Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–6.PubMedPubMedCentralCrossRef
54.
Guieze R, Ysebaert L, Roos-Weil D, Fornecker L-M, Ferrant E, Molina L, et al. Blinatumomab for patients with Richter syndrome: final results of the phase 2 Blinart trial from the Filo group. Blood. 2022;140(Supplement 1):6631–2.CrossRef
55.
Guieze R, Ysebaert L, Roos-Weil D, Molina L, Fornecker LM, Aurran T, et al. Blinatumomab for patients with Richter's syndrome: a multicenter phase 2 trial from the Filo group. Blood. 2021;138(Supplement 1):3570.CrossRef
56.
Kater AP, Ye JC, Sandoval-Sus J, Bellido M, Christensen JH, Mato AR, et al. Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). Blood. 2022;140(Supplement 1):850–1.CrossRef
57.
Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. J Clin Oncol. 2023;41(16_suppl):7525.CrossRef
58.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959–70.PubMedPubMedCentralCrossRef
59.
•• Carlo-Stella C, Hutchings M, Offner F, Mulvihill E, Relf J, Byrne B, et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter’s transformation. Hematol Oncol. 2023;41(S2):63–5. Bispecific antibodies are an exciting new treatment modality for NHL, in this study of patients with RT, the efficacy of this therapy shown is promising.CrossRef
60.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–15.PubMedCrossRef
61.
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675–84.PubMedCrossRef
62.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, et al. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. Blood Adv. 2020;4(19):4648–52.PubMedPubMedCentralCrossRef
63.
Benjamini O, Shimoni A, Besser M, Shem-Tov N, Danylesko I, Yerushalmi R, et al. Safety and efficacy of CD19-CAR T cells in Richter's transformation after targeted therapy for chronic lymphocytic leukemia. Blood. 2020;136:40.CrossRef
64.
Ortiz-Maldonado V, Frigola G, Español-Rego M, Balagué O, Martínez-Cibrián N, Magnano L, et al. Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter’s transformation. Front Oncol. 2022;12:828471.PubMedPubMedCentralCrossRef
65.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.PubMedCrossRef
66.
Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010–20.PubMedPubMedCentralCrossRef
67.
Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(18):2211–7.PubMedCrossRef
68.
Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016;22(12):2117–25.PubMedPubMedCentralCrossRef
69.
Aulakh S, Reljic T, Yassine F, Ayala E, Chavez JC, Chanan-Khan A, et al. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021;14(1):33–40.PubMedCrossRef
70.
Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, et al. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021;106(12):3219–22.PubMedPubMedCentralCrossRef
71.
Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021;5(18):3528–39.PubMedPubMedCentralCrossRef
72.
Spurgeon SE, Mei M, Barr PM, Barrientos JC, de Vos S, Furman RR, et al. Waveline-001: updated results from a phase 1 dose escalation and cohort expansion study of zilovertamab vedotin (MK-2140) in non-Hodgkin lymphoma. Blood. 2022;140(Supplement 1):6640–1.CrossRef
73.
Huntington SF, Schuster SJ, He W, Shen T, Walker H, Leary L, et al. Phase I study of first-in-class oral triplet therapy DTRM-555 in relapsed/refractory lymphoma patients through fixed-dose combination and synthetic lethality. Blood. 2018;132(Supplement 1):5384.CrossRef
74.
Sharp A, Williams A, Blagden S, Plummer R, Hochhauser D, Krebs MG, et al. PB2099: A first-in-human phase 1 trial of NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies including Richter transformation DLBCL. Hemasphere. 2022;6.
75.
Bhagwat N, Ruggeri B, Zhang Y, Mosesson Y, Killick-Cole C, Jagannathan V, et al. PRT2527, a novel highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, has potent anti-leukemic activity in preclinical primary models of human B-ALL, T-ALL, and CLL. Blood. 2022;140(Supplement 1):505–6.CrossRef
76.
Mandal R, Becker S, Strebhardt K. Targeting CDK9 for anti-cancer therapeutics. Cancers (Basel). 2021;13(9)
Metadata
Title
Treatment of Richter’s Transformation with Novel Therapies
Authors
Amneet Bajwa
Alma Habib
Adam S. Kittai
Publication date
09-01-2024
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 2/2024
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-023-00721-8

Other articles of this Issue 2/2024

Current Hematologic Malignancy Reports 2/2024 Go to the issue

ReviewPaper

How Do We Manage Chronic Lymphocytic Leukemia in India

ReviewPaper

Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations

ReviewPaper

Frontline Therapy of CLL—Changing Treatment Paradigms

ReviewPaper

Transplantation and Cellular Therapy for Older Adults—The MSK Approach
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits